Moderna (MRNA) EBT Margin (2017 - 2026)
Moderna's (MRNA) quarterly EBT Margin came in at 528.97% in Q2 2026, up 4709.0% year-over-year from 11.0% in Q2 2025, and down 54.25% quarter-over-quarter from 342.93% in Q1 2026.
Powered by 
Analysis
Moderna (MRNA) EBT Margin (2017 - 2026) Analysis & Trends
Moderna (MRNA) has reported EBT Margin for 10 consecutive years, with 528.97% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin rose 4709.0% year-over-year to 528.97% in Q2 2026; TTM through Jun 2026 was 138.55%, a 4288.0% decrease from a year earlier, with the FY2025 full-year figure at 142.39%, down 3092.0% from the prior year.
- EBT Margin was 528.97% for Q2 2026 at Moderna, down from 342.93% in the prior quarter.
- Over five years, EBT Margin peaked at 69.72% in Q1 2022 and troughed at 892.59% in Q1 2025.
- A 5-year average of 236.96% and a median of 112.39% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 68122 bps in 2024 and surged 54966 bps in 2026, its largest moves.
- Over 5 years, EBT Margin stood at 32.55% in 2022, then plunged by 92 bps to 2.49% in 2023, then plunged by 5022 bps to 122.57% in 2024, then climbed by 4 bps to 117.85% in 2025, then slumped by 349 bps to 528.97% in 2026.
- The last three EBT Margin figures came in at 528.97% (Q2 2026), 342.93% (Q1 2026), and 117.85% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 4.84% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -2.67% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -813.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -528.97% |
| Mar 31, 2026 | -342.93% |
| Dec 31, 2025 | -117.85% |
| Sep 30, 2025 | -18.41% |
| Jun 30, 2025 | -576.06% |
| Mar 31, 2025 | -892.59% |
| Dec 31, 2024 | -122.57% |
| Sep 30, 2024 | 1.13% |
| Jun 30, 2024 | -530.71% |
| Mar 31, 2024 | -697.60% |
| Dec 31, 2023 | 2.49% |
| Sep 30, 2023 | -106.94% |
| Jun 30, 2023 | -508.43% |
| Mar 31, 2023 | -16.38% |
| Dec 31, 2022 | 32.55% |
| Sep 30, 2022 | 36.18% |
| Jun 30, 2022 | 52.10% |
| Mar 31, 2022 | 69.72% |
| Dec 31, 2021 | 75.02% |
| Sep 30, 2021 | 71.48% |